COPENHAGEN, Denmark; August 8, 2022 -Genmab A/S (Nasdaq:GMAB) announced today that it is improving its 2022 financial guidance published on May 11, 2022. The improved guidance is driven primarily by increased royalty revenue due to higher net sales of DARZALEX and the positive net foreign exchange impact of the strong U.S. Dollar.

Genmab expects its 2022 revenue to be in the range of DKK 12,000 - 13,000 million, an increase to the previous guidance of DKK 11,000 - 12,000 million, driven primarily by the continued strong growth of DARZALEX net sales as well as the positive impact of the strong U.S. Dollar. Genmab's projected revenue for 2022 primarily consists of DARZALEX royalties. Such royalties are based on Genmab's revised estimate of DARZALEX 2022 net sales of USD 7.8 - 8.2 billion compared to Genmab's previous estimate of USD 7.5 - 8.0 billion.